argenx NV ADR (ARGX)vsEffector Therapeutics Inc (EFTR)
ARGX
argenx NV ADR
$697.05
+2.89%
HEALTHCARE · Cap: $42.05B
EFTR
Effector Therapeutics Inc
$0.00
0.00%
HEALTHCARE · Cap: $940
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 627525% more annual revenue ($4.24B vs $675,000). ARGX leads profitability with a 30.5% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 63/100 (C+).
ARGX
Buy63
out of 100
Grade: C+
EFTR
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-526.8%
Fair Value
$133.14
Current Price
$697.05
$563.91 premium
Intrinsic value data unavailable for EFTR.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Revenue surging 73.0% year-over-year
Every $100 of equity generates 20 in profit
Growing faster than its price suggests
Strong operational efficiency at 27.4%
Reasonable price relative to book value
Revenue surging 117.0% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 31.9%
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 30.5% and operating margin at 27.4%. Revenue growth of 73.0% demonstrates continued momentum.
Bull Case : EFTR
The strongest argument for EFTR centers on Price/Book, Revenue Growth. Revenue growth of 117.0% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, EPS Growth.
Bear Case : EFTR
The primary concerns for EFTR are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ARGX profiles as a growth stock while EFTR is a hypergrowth play — different risk/reward profiles.
EFTR carries more volatility with a beta of 0.96 — expect wider price swings.
EFTR is growing revenue faster at 117.0% — sustainability is the question.
ARGX generates stronger free cash flow (407M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (63/100 vs 34/100), backed by strong 30.5% margins and 73.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Effector Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Effector Therapeutics Inc (EFTR) is a clinical-stage biopharmaceutical company pioneering targeted cancer therapies through the selective modulation of RNA translation. By specifically altering protein synthesis within tumor cells, the company is addressing critical unmet needs in oncology with its innovative small molecule treatments. With a robust and diverse pipeline of candidates under development, Effector Therapeutics is dedicated to advancing precision medicine, ultimately striving to improve treatment outcomes and quality of life for cancer patients in an evolving biotechnology landscape.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?